What Is Poziotinib And Where To Buy The Best Poziotinib Peptide

Page 1

WhatIsPoziotinibAndWhereToBuyTheBestPoziotinibPeptide -ByPhcoker

PoziotinibStructure

Sequence: /

Molecular

Formula: C23H21Cl2FN4O3

Molecular Weight: 49134g/mol

PubChemCID:25127713

CASNumber:1092364-38-9

Synonyms: NOV120101,HM781-36B,UNII-OEI6OOU6IK

1.PoziotinibHistory

Poziotinib(NOV120101,HM781-36B)isadrugindevelopmentbyHanmiPharmaceutical(SouthKorea), LuyePharma(China),andSpectrumPharmaceuticals(restoftheworld)forvariouscancers Builtonananilino-quinazolinescaffold,PoziotinibinhibitstheepidermalgrowthfactorreceptorsEGFR, HER2/neu,andHER4bybindingcovalentlytoitstargetsThismechanismblocksthetyrosinekinase

PeptideGMPManufacturers www.phcoker.com

activityofthesereceptors,impedingdownstreamsignalingpathwaysessentialfortumorcellproliferation andsurvival,ultimatelyleadingtocelldeath

DiscoveredbyHanmiPharmaceutical,Poziotinib'sdevelopmenthasinvolvedstrategiclicensing agreements

InAugust2014,HanmiexclusivelylicensedtherightsforChinatoLuyePharma; InFebruary2015,theylicensedtherightsfortherestoftheworldoutsideSouthKoreatoSpectrum Pharmaceuticals

Asof2016,SpectrumPharmaceuticalsinitiatedaPhaseIIclinicaltrialofPoziotinibasasecond-line treatmentforbreastcancer

DevelopmentTimelineforPoziotinib

Date Article

Nov25,2022

Sep22,2022

Feb11,2022

Dec6,2021

Mar11,2021

Sep24,2018

SpectrumPharmaceuticalsReceivesCompleteResponseLetter fromUSFoodandDrugAdministrationforPoziotinib

SpectrumPharmaceuticalsProvidesUpdateonPoziotinibFollowing FDAOncologicDrugsAdvisoryCommitteeMeeting

SpectrumPharmaceuticalsAnnouncesAcceptanceofNewDrug ApplicationFilingforPoziotinib

SpectrumPharmaceuticalsAnnouncesAcceptanceofNewDrug ApplicationFilingforPoziotinib

FDAGrantsFastTrackDesignationtoSpectrumPharmaceuticals’ Poziotinib

SpectrumPharmaceuticalsAnnouncesReleaseofUpdated PoziotinibDataFromMDAndersonPhase2StudyinNon-SmallCell LungCancerPatients

PoziotinibResearchesonCancers

PoziotinibhasbeeninvestigatedinclinicaltrialsforthetreatmentofvariouscancersSomeofthe specificconditionsstudiedinclude:

PeptideGMPManufacturers www.phcoker.com

BreastCancer

MetastaticBreastCancer

IncreasedDrugResistance

AdenocarcinomaofLungStageIV

AdenocarcinomaofLungStageIIIB

ThesetrialsexploretheeffectivenessofPoziotinibintargetingcancersthatoverexpressorhave mutationsintheepidermalgrowthfactorreceptors(EGFR),includingHER2andHER4Itsuseis particularlyfocusedoncancerswithEGFRexon20insertionmutations

2.WhatisPoziotinib?

Poziotinibpeptideisanorallybioavailable,quinazoline-based,small-molecule,irreversible pan-epidermalgrowthfactorreceptor(EGFRorHER)inhibitorwithpotentialantineoplasticactivity.It inhibitsEGFR(HER1orErbB1),HER2,HER4,andEGFRmutants,therebyhinderingtheproliferationof tumorcellsthatoverexpressthesereceptors.EGFRs,whicharecellsurfacereceptortyrosinekinases, arefrequentlyupregulatedinvariouscancercelltypesandplaycrucialrolesincellularproliferationand survival

Poziotinibhasbeeninvestigatedinclinicaltrialsforthetreatmentofvariouscancers,includingbreast cancer,metastaticbreastcancer,increaseddrugresistance,adenocarcinomaofthelung(StageIVand StageIIIB),amongothers.

Foryoursafety,pleasebuyandusePoziotinibwithcaution

3.WhataretheMechanismofPoziotinib?

ThemechanismofactionofPoziotinibinvolvesitssmallsizeandflexiblestructure,whichallowitto accesstherestrictedbindingsitesofepidermalgrowthfactorreceptors(EGFRs),includingHER1 (ErbB1),HER2,andHER4,aswellasEGFRmutantsByovercomingthesterichindrancethatmight impedeothermolecules,Poziotinibeffectivelybindstothesereceptorsandinhibitstheirtyrosinekinase activity

PeptideGMPManufacturers www.phcoker.com

Inhibitionoftyrosinekinaseactivityblocksthedownstreamsignalingpathwaysthatarecriticalforcell proliferationandsurvivalAsaresult,thisleadstothedisruptionofcellularprocessesessentialfortumor growthandprogression,ultimatelycausingcelldeathThismechanismmakesPoziotinibapotent antineoplasticagent,particularlyeffectiveagainstcancerswithoverexpressedormutatedEGFRs

Ifyouarefacingtheproblemofcancerresearch,youmightaswelltrytobuyPoziotinibforatryBesure tobuyPoziotinibfromaregularsource,buyPoziotinibonlineisnotabadchoice,theimportantistofind areliablePoziotinibmanufacturer

4.WhatBenefitsCanYouGetFromPoziotinibonNSCLC?

TheantitumoractivityofpoziotinibwasfoundtobesignificantinpatientswithEGFRexon20positive non–smallcelllungcancer(NSCLC).Theefficacyofthetreatmentwasfoundtobehighlydependenton thelocationoftheexon20loopinsertionThesefindingswerepublishedinCancerCellTheresults werepublishedinCancerCell

Thestudy,designatedasphase2(NCT03066206),included50patientswithadvancednon-smallcell lungcancer(NSCLC)whoexhibitedpointmutationsorinsertionsintheEGFRexon20Thestudy achieveditsprimaryendpointwithaconfirmedobjectiveresponserate(ORR)of32%(95%CI, 20.7%-45.8%)and31%(95%CI,19.1%-46%)byinvestigatorandblindedindependentreview, respectively

PeptideGMPManufacturers www.phcoker.com

Moreover,researchersfoundamedianprogression-freesurvival(PFS)of5.5months(95%CI,5.4-10.4) withaPFSrateof43%(95%CI,30%-60%)at6months,and29%(95%CI,18%-46%)at12months

Medianoverallsurvivalalsoappearedtobebeneficialat192months(95%CI,118-241)withadisease controlrateof84%(95%CI,715%-92%)

“EGFRexon20mutantlungcancerstypicallydon’trespondwelltothetypesoftyrosinekinaseinhibitors thathavebeenlargelysuccessfulintargetingclassicalEGFRmutations,leavingthispatientpopulation withfeweffectivetreatmentoptions,”saidseniorauthorofthestudy,JohnHeymach,MD,PhD,chairof theThoracic/Head&NeckMedicalOncologyattheMDAndersonCancerCenter,inapressrelease.2

“Ourstudygiveshopefornotonlyapotentiallybeneficialtreatmentoption,butforanewlevelof precisiontobettertargetEGFRexon20mutationsandtodesignmoreeffectiveclinicaltrials”

AnewdrugapplicationforpoziotinibwasacceptedbytheFDAforpatientswithadvancedormetastatic NSCLCharboringHER2exon20insertionmutationsinFebruary2022Poziotinibalsoreceivedfast trackdesignationfromtheFDAinMarch2021forpatientswithHER2exon20insertion–mutated NSCLC.

5.SideeffectsofSemaglutide

Poziotinib,likemanytargetedcancertherapies,isassociatedwitharangeoftreatment-relatedadverse events(TRAEs)AlmostallpatientsenrolledinclinicaltrialsexperiencedTRAEsofanygradeThemost commonsideeffectsinclude:

PeptideGMPManufacturers www.phcoker.com

Diarrhea:Experiencedby79%ofpatients

Rash:Experiencedby60%ofpatients

Stomatitis(inflammationofthemouth):Experiencedby52%ofpatients

Paronychia(nailinfection):Experiencedby45%ofpatients

Severe(Grade3)TRAEswerealsoreportedinasignificantproportionofpatients,occurringin60%of casesThemostcommonseveresideeffectsinclude:

Diarrhea:Experiencedby25%ofpatients

Rash:Experiencedby28%ofpatients

Thesesideeffectshighlighttheneedforcarefulmanagementandmonitoringofpatientsundergoing treatmentwithPoziotinib

ReferencedCitations

[1]LeX,CornelissenR,GarassinoM,etalPoziotinibinNon-Small-CellLungCancerHarboringHER2 Exon20InsertionMutationsAfterPriorTherapies:ZENITH20-2TrialJClinOncol2022;40(7):710-771

[2]Phase2StudyofPoziotinibinPatientsWithNSCLCHavingEGFRorHER2Exon20Insertion Mutation.AccessedonJune5,2022.

PeptideGMPManufacturers www.phcoker.com

[3]ElaminYY,RobichauxJP,CarterBW,etalPoziotinibforPatientsWithHER2Exon20Mutant Non-Small-CellLungCancer:ResultsFromaPhaseIITrialJClinOncol2022;40(7):702-709

[4]SpectrumPharmaceuticalsreceivescompleteresponseletterfromusfoodanddrugadministration forpoziotinib;ReaffirmsfocusonthecommercializationofROLVEDON™(eflapegrastim-xnst)injection NewsreleaseSpectrumPharmaceuticalsNovember25,2022AccessedNovember28,2022

[5]LeX,CornelissenR,GarassinoM,etal.Poziotinibinnon-small-celllungcancerHarboringHER2 exon20insertionmutationsafterpriortherapies:ZENITH20-2Trial.JClinOncol.2022;40(7):710-718. doi:10.1200/JCO.21.01323

[6]KimM(4July2016)"HanmiPharmaceuticaltoStepUpR&DInvestmenttoFurtherDevelopCore Technologies"BusinessKorea

[7]RoskoskiR(September2014)"ErbB/HERprotein-tyrosinekinases:Structuresandsmallmolecule inhibitors"PharmacologicalResearch87:42–59doi:101016/jphrs201406001PMID24928736

[8]Poziotinib"NCIDrugDictionaryNationalCancerInstitute,NationalInstitutesofHealth,US DepartmentofHealthandHumanServicesRetrieved25March2017

[9]J.RobertMcCorkle,JustinW.Gorski,JinpengLiu,etal.Lapatinibandpoziotinibovercome ABCB1-mediatedpaclitaxelresistanceinovariancancer,PLOSONE(2021) DOI:101371/journalpone0254205

[10]OncologicDrugsAdvisoryCommittee(ODAC)MeetingFDASeptember22,2022Accessed November28,2022

[11]SpectrumPharmaceuticalsannouncesacceptanceofnewdrugapplicationfilingforpoziotinib NewsreleaseSpectrumPharmaceuticalsFebruary11,2022AccessedNovember28,2022

[12]SchulerM,AwadaA,HarterP,CanonJL,PossingerK,SchmidtM,etal.(August2012)."AphaseII trialtoassessefficacyandsafetyofafatinibinextensivelypretreatedpatientswithHER2-negative metastaticbreastcancer"BreastCancerResearchandTreatment134(3):1149–59 doi:101007/s10549-012-2126-1PMC3409367PMID22763464

[13]LinNU,WinerEP,WheatleyD,CareyLA,HoustonS,MendelsonD,etal(June2012)"AphaseII studyofafatinib(BIBW2992),anirreversibleErbBfamilyblocker,inpatientswithHER2-positive metastaticbreastcancerprogressingaftertrastuzumab"BreastCancerResearchandTreatment133 (3):1057–65

PeptideGMPManufacturers www.phcoker.com

[14]LiD,AmbrogioL,ShimamuraT,KuboS,TakahashiM,ChirieacLR,etal(August2008) "BIBW2992,anirreversibleEGFR/HER2inhibitorhighlyeffectiveinpreclinicallungcancermodels"

Oncogene27(34):4702–11doi:101038/onc2008109PMC2748240PMID18408761

[15]MillerVA,HirshV,CadranelJ,ChenYM,ParkK,KimSW,etal(May2012)"Afatinibversus placeboforpatientswithadvanced,metastaticnon-small-celllungcancerafterfailureoferlotinib, gefitinib,orboth,andoneortwolinesofchemotherapy(LUX-Lung1):aphase2b/3randomisedtrial".

TheLancet.Oncology.13(5):528–38.doi:10.1016/S1470-2045(12)70087-6.PMID22452896.

Authorofthisarticle:

DrJeanZenggraduatedfromking’scollegelondonFacultyofLifeSciences&Medicine

ScientificJournalpaperAuthor:

1RobinCornelissenMD,PhD

PulmonaryMedicine,ErasmusMCCancerInstitute,Rotterdam,TheNetherlands

2.YasirY.Elamin

DepartmentofThoracic/HeadandNeckMedicalOncology,TheUniversityofTexasMDAnderson CancerCenter,Unit432,POBox301402,1500HolcombeBoulevard,Houston,TX77030,USA

3XLe

MDAndersonCancerCenter,Houston/TX/USA

4FrankJBormMD

DepartmentofPulmonaryDiseases,LeidenUniversityMedicalCentre,Leiden,TheNetherlands

5.ReidOldenburgMD,PhD

DepartmentofDermatology,UniversityofCaliforniaSanDiego,LaJolla,SanDiego,California

PeptideGMPManufacturers www.phcoker.com

Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.